1-4 of 4
Donald A. Berry
Close
Sort by
Journal Articles

Phase I/II Study of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) In Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma

Anas Younes, MD, Amanda Copeland, MSN, Michelle A. Fanale, MD, Fredrick Hagemeister, MD, Luis Fayad, MD, Barbara Pro, MD, Silvana C. Faria, MD, PhD, Yuan Ji, PhD, L. Jeffrey Medeiros, MD, Donald A Berry, PhD, Daniela Buglio, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 3964.
https://doi.org/10.1182/blood.V116.21.3964.3964
Published: 2010
Journal Articles

Incremental Benefit of Histamine Dihydrochloride When Added to Interleukin-2 for Remission Maintenance In Acute Myeloid Leukemia: A Bayesian Meta-Analysis

Scott M. Berry, PhD, Kristine R. Broglio, MS, Donald A. Berry, PhD
Journal: Blood
Blood (2010) 116 (21): 2182.
https://doi.org/10.1182/blood.V116.21.2182.2182
Published: 2010
Journal Articles

Vaccination with IgM but Not IgG Idiotype Prolongs Remission Duration In Follicular Lymphoma Patients

Stephen J. Schuster, Carlos F. Santos, Sattva S. Neelapu, Donald A. Berry, Mihaela A. Popa, Amy M. McCord, Elise A. Chong, Larry Kwak
Journal: Blood
Blood (2010) 116 (21): 429.
https://doi.org/10.1182/blood.V116.21.429.429
Published: 2010
Journal Articles

The Pan-Deacetylase Inhibitor Panobinostat Downregulates HIF-1α and VEGF and, Synergizes with Everolimus In Hodgkin Lymphoma Cell Lines

Manuela Lemoine, PhD, Daniela Buglio, MD, PhD, Adam Jona, Enrico Derenzini, MD, L. Jeffrey Medeiros, MD, Donald A Berry, PhD, Anas Younes, MD
Journal: Blood
Blood (2010) 116 (21): 2851.
https://doi.org/10.1182/blood.V116.21.2851.2851
Published: 2010